- Home
- INDO vs QNCX Comparison
INDO vs QNCX Comparison
Compare INDO & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDO
- QNCX
- Stock Information
- Founded
- INDO 2018
- QNCX 2012
- Country
- INDO Indonesia
- QNCX United States
- Employees
- INDO N/A
- QNCX N/A
- Industry
- INDO Oil & Gas Production
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INDO Energy
- QNCX Health Care
- Exchange
- INDO Nasdaq
- QNCX Nasdaq
- Market Cap
- INDO 40.1M
- QNCX 44.0M
- IPO Year
- INDO 2019
- QNCX 2019
- Fundamental
- Price
- INDO $2.28
- QNCX $1.03
- Analyst Decision
- INDO
- QNCX Strong Buy
- Analyst Count
- INDO 0
- QNCX 5
- Target Price
- INDO N/A
- QNCX $8.00
- AVG Volume (30 Days)
- INDO 188.8K
- QNCX 128.6K
- Earning Date
- INDO 04-29-2025
- QNCX 05-12-2025
- Dividend Yield
- INDO N/A
- QNCX N/A
- EPS Growth
- INDO N/A
- QNCX N/A
- EPS
- INDO N/A
- QNCX N/A
- Revenue
- INDO $3,127,587.00
- QNCX N/A
- Revenue This Year
- INDO N/A
- QNCX N/A
- Revenue Next Year
- INDO N/A
- QNCX N/A
- P/E Ratio
- INDO N/A
- QNCX N/A
- Revenue Growth
- INDO N/A
- QNCX N/A
- 52 Week Low
- INDO $2.06
- QNCX $0.51
- 52 Week High
- INDO $5.88
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- INDO 43.27
- QNCX 32.65
- Support Level
- INDO $2.21
- QNCX $0.98
- Resistance Level
- INDO $2.49
- QNCX $1.10
- Average True Range (ATR)
- INDO 0.16
- QNCX 0.10
- MACD
- INDO -0.00
- QNCX -0.00
- Stochastic Oscillator
- INDO 35.08
- QNCX 22.94
About INDO Indonesia Energy Corporation Limited
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.